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Background: Development of acquired resistance limits the utility 
of epidermal growth factor receptor (EGFR) tyrosine kinase inhibi-
tors (TKI) for the treatment of EGFR-mutant lung cancers. There 
are no accepted targeted therapies for use after acquired resistance 
develops. Metastasectomy is used in other cancers to manage oligo-
metastatic disease. We hypothesized that local therapy is associated 
with improved outcomes in patients with EGFR-mutant lung cancers 
with acquired resistance to EGFR TKI.
Methods: Patients who received non–central nervous system local 
therapy were identified by a review of data from a prospective biopsy 
protocol for patients with EGFR-mutant lung cancers with acquired 
resistance to EGFR TKI therapy and other institutional biospecimen 
registry protocols.
Results: Eighteen patients were identified, who received elective 
local therapy (surgical resection, radiofrequency ablation, or radia-
tion). Local therapy was well tolerated, with 85% of patients restart-
ing TKI therapy within 1 month of local therapy. The median time 
to progression after local therapy was 10 months (95% confidence 
interval [CI]: 2–27 months). The median time until a subsequent 
change in systemic therapy was 22 months (95% CI: 6–30 months). 
The median overall survival from local therapy was 41 months (95% 
CI: 26–not reached).
Conclusions: EGFR-mutant lung cancers with acquired resistance 
to EGFR TKI therapy are amenable to local therapy to treat oligo-
metastatic disease when used in conjunction with continued EGFR 
inhibition. Local therapy followed by continued treatment with an 
EGFR TKI is well tolerated and associated with long PFS and OS. 
Further study in selected individuals in the context of other systemic 
options is required.
Key Words: EGFR-mutant lung cancer, Acquired resistance 
to epidermal growth factor receptor tyrosine kinase inhibitors, 
Metastasectomy, Local therapy.
(J Thorac Oncol. 2013;8: 346–351)
Non–small-cell lung cancers have increasingly become divided into molecular subsets with genomic alterations 
such as EGFR, KRAS, and ALK,1,2 having both therapeutic 
and prognostic implications. More recently, driver molecular 
alterations in RET and ROS1 have joined the growing list of 
actionable oncogene-dependent cancers.3,4 Epidermal growth 
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefi-
tinib and erlotinib induce preferential responses in patients 
with EGFR mutations.1,5,6 In prospective studies, gefitinib, 
erlotinib, and afatinib treatment are associated with longer 
progression-free survival and higher radiographic response 
rates than treatment with standard first-line chemotherapy.7–11
Despite the initial success of these agents, all patients 
progress, with a median progression-free survival of 12 to 
16 months.7–12 Acquired resistance to EGFR TKIs has been 
attributed to several molecular mechanisms, although the 
etiology of resistance remains unknown in approximately 35% 
of patients.13 The most common etiologies of resistance are the 
development of the T790M missense mutation,14 amplification 
of MET,15,16 and, in rare instances, transformation to small-cell 
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histology.17 Despite clinical evidence of progression on EGFR 
TKI therapy, continued EGFR inhibition seems to provide 
continued clinical benefit.18,19 Standard cytotoxic chemotherapy 
is typically combined with or substituted for an EGFR TKI 
at progression. The combination of cytotoxic chemotherapy 
and EGFR TKIs has been assessed in the first-line setting 
with comparable toxicity to chemotherapy alone.12 Small 
series indicate a higher response rate with chemotherapy and 
continued EGFR TKI compared with chemotherapy alone in the 
acquired resistance setting.20 There are currently no approved 
targeted therapies available for use in the acquired resistance 
setting, although evaluation of second-generation, irreversible 
EGFR TKIs, other novel agents, and combinations are ongoing.
Local therapies including radiation, radiofrequency abla-
tion, and metastasectomy are established treatment strategies 
in certain cancers including renal cell carcinoma, sarcoma, and 
colorectal cancer. Such approaches are now recommended in 
the National Comprehensive Cancer Network (NCCN) guide-
lines for oligometastatic disease.21–25 The definition of oligo-
metastatic disease varies, but typically indicates fewer than five 
discrete sites of disease. The ideal candidate for local therapy is 
a patient with oligometastatic disease where the primary tumor 
is controlled and surgical resection may render the patient 
free of disease. In selected patients, long-term survival ben-
efits can exceed those achieved with systemic therapy alone.26 
Prognostic factors that are used for selection of patients for 
metastasectomy, in general, reflect slower growing disease.27–29
Local therapy is not commonly used in metastatic lung 
cancer. Although some case reports and retrospective series 
indicate potential benefit in surgical resection or radiation 
therapy of oligometastatic disease, specifically within the 
lung, adrenal gland or central nervous system,30–33 other series 
do not support this.34 EGFR-mutant lung cancers treated with 
EGFR TKI therapy typically have a longer clinical course than 
EGFR–wild-type disease treated with cytotoxic chemotherapy, 
suggesting that these patients may be an appropriate group 
of patients to study the utility of local therapy. We chose to 
investigate the efficacy of local therapy with continued EGFR 
TKI therapy specifically in patients with acquired resistance to 
EGFR TKIs. We hypothesized that local therapy is associated 
with improved outcomes in patients with EGFR-mutant lung 
cancers with acquired resistance to EGFR TKI therapy.
MATERIALS AND METHODS
Design
To be included in this analysis, patients had to have 
EGFR-mutant lung cancer previously treated with erlotinib or 
gefitinib, documented progression on EGFR TKI therapy, and 
then undergone radiation therapy, radiofrequency ablation, or 
surgical treatment of a site of progressive disease. Patients were 
identified from a cohort of patients who had consented to a pro-
spective rebiopsy protocol of patients with acquired resistance 
to EGFR TKIs or other Institutional Review Board-approved 
biospecimen protocols. Postoperative adverse events were 
graded using Common Toxicity Criteria Adverse Events v. 4.0. 
Data collection was approved by the Memorial Sloan-Kettering 
Cancer Center Institutional Review Board/Privacy Board.
We collected clinical characteristics and treatment course 
for all subjects, including the type of EGFR mutation as well 
as the mechanism of acquired resistance if identified. Both the 
clinical course on EGFR-directed therapy and treatment regi-
mens after progression on EGFR TKI were documented. Local 
interventions including surgical resection, radiofrequency 
ablation, stereotactic radiosurgery, and conventional radiation 
therapy were recorded. As local therapy for brain metastases 
is considered standard of care, brain metastases treated with 
local therapy were not included in this analysis. Outcomes of 
interest were time to progression, time until change in sys-
temic therapy and overall survival from time of local therapy. 
The date of progression was defined based on routine surveil-
lance imaging and/or symptomatic progression that prompted 
earlier radiographic evaluation with routine imaging every 2 
to 3 months for most patients. Time until change in systemic 
therapy was noted when a change in therapy occurred, which 
included the addition of cytotoxic chemotherapy or enroll-
ment on to a clinical trial.
Statistical Analysis
Patients who did not receive local therapy but signed 
consent for a prospective study of patients with acquired 
resistance were used as a comparison group. Distribution of 
clinical variables was compared across patients with EGFR-
mutant lung cancers with acquired resistance who had and 
did not have local therapy, using Wilcoxon rank-sum test (for 
continuous variables) and Fisher’s exact test (for categorical 
variables). Time to progression and overall survival were mea-
sured starting from the time of local therapy until progression 
and death, respectively, using Kaplan–Meier method. Patients 
who did not experience progression or death during the study 
time were censored at the time of the last available follow-up.
RESULTS
Intracranial Procedures
Of 184 patients identified with acquired resistance to 
EGFR TKI, 42 patients developed brain metastases during 
their treatment course, which required one or more central 
nervous system (CNS)–directed interventions. Eight patients 
underwent craniotomy for surgical resection of solitary or 
oligometastatic brain metastases. Ten patients had stereotactic 
radiosurgery and 28 patients had whole-brain radiation ther-
apy. As local therapy for brain metastases is considered stan-
dard of care, treatment of brain metastases with local therapy 
was not included in this analysis. Two of the 42 patients who 
had CNS interventions also had local therapy to a non-CNS 
site; these non-CNS procedures were included in this analysis.
Clinical and Molecular Characteristics
Eighteen patients had one or more local therapies, 
excluding intracranial treatments, for advanced EGFR-mutant 
lung cancers. The median time from the diagnosis of advanced 
disease to local therapy was 26 months (11–57 months). All 
patients except one had oligometastatic disease (<5 sites of 
disease) at the time of local therapy. The clinical and molecular 
characteristics of these patients are noted in Table 1. There was 
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no significant difference in age, sex, ethnicity, smoking history, 
stage at diagnosis, and sites of metastatic disease between the 
group that received local therapy and patients who received 
systemic therapy only. Patients in the local therapy group 
had a nonsignificant longer time to progression on EGFR 
TKI therapy before local therapy (p = 0.09). Mechanisms 
of resistance were similar in both groups, with the acquired 
T790M point mutation being most common, followed by MET 
amplification and small-cell histologic transformation. One 
patient in the local therapy group had an acquired PIK3CA 
mutation.
Procedures and Postprocedure Course
The local therapies are detailed in Table 2. Most patients 
had surgical resections of pulmonary metastases. Fifteen of 
18 patients had local therapy performed within 4 months of 
radiographic progression on EGFR TKI. The remaining three 
patients had other systemic therapy (clinical trial or addition of 
chemotherapy) before local therapy. Most local therapies were 
well tolerated. Three patients had postoperative complications 
and prolonged hospitalizations (10 days–1 month). One patient 
TABLE 1.  Patient Characteristics
Local Therapy 
Patients
Systemic Therapy 
Patients p
Characteristic n = 18 n = 166
Age (yr)
 Median 57 58 0.67
 Range 44–69 26–86
Sex (%)
 Male  8 (44) 56 (34) 0.44
 Female 10 (56) 110 (66)
Ethnicity (%)
 White 13 (72) 116 (70) *0.99
 Asian  4 (22) 34 (20)
 Black  1 (6) 14 (8)
 Other  0 2 (1)
Smoking history (%)
 Never-smoker 11 (61) 116 (70) 0.43
 Former smoker  7 (39) 50 (30)
 Median pack yr 20 16
 Range 1–56 1–60
Stage at initial diagnosis (%)
 I–II  2 (11) 22 (13) 0.55
 IIIA–IIIB  3 (17) 15 (9)
 IVA–IVB 13 (72) 129 (78)
Site of metastatic disease
 Lung 14 139 0.59
 Brain  3 41
 Bone  4 65
 Lymph node  8 50
 Visceral (liver,  
spleen, etc.)
 2 32
EGFR mutation type (%)
 Exon 19 deletion 14 (78) 109 (66) 0.63
 Exon 21 L858R  4 (22) 53 (32)
 Other  0 4 (2)
Best response to TKI
 Complete response  1  2 0.70
 Partial response 13 130
 Stable disease  1 19
 Adjuvant therapy  3 13
 Progression disease  0  2
Initial EGFR TKI TTP (mo)
 Median 19 12 0.089
 Range 5–33 2–73
Resistance mechanism, no. (%)
 T790M 11 (61%) 84 (51%) **0.63
 MET amplification  1  5
 Small-cell histology  1  3
 Unknown  6 75
* p value for White vs. all others is 0.99.
** p value for T790M group vs. all others is 0.63.
EGFR, epidermal growth factor receptor; TKI tyrosine kinase inhibitor; TTP, time 
to progression.
TABLE 2.  Procedures 
Performed
Total 18
Lung 15
 Radiofrequency ablation 2
 Stereotactic radiotherapy 1
 Radiation therapy 1
 Lobectomy 7
 Wedge resection 1
 Pneumonectomy 3
Lymph node (supraclavicular)
 Radiation therapy 1
Adrenal gland
 Adrenalectomy 2
FIGURE 1.  Time to progression after local therapy.
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had grade 2 postoperative atrial fibrillation, one had grade 3 
postoperative pneumonia and hypoxia, and one had grade 4 
postoperative pneumonia and acute respiratory distress syn-
drome. Thirteen of 18 patients had no radiographic evidence 
of disease after local therapy. Fifteen of 18 patients resumed 
erlotinib or gefitinib within 1 month of local therapy. In the 
remaining three patients, EGFR TK therapy was not restarted 
because there was no evidence of disease after local therapy.
 Outcomes
Thirteen of the 18 patients progressed after local ther-
apy during the study period, and eight of 18 patients died. Of 
the 13 patients who progressed, 12 progressed with distant 
metastatic disease, and one progressed with locally recurrent 
disease only. The patient who progressed locally had an extra-
pleural pneumonectomy, and progressed after 28 months. The 
median time to progression after local therapy was 10 months 
(95% CI: 2–27 months), with a range from 1 to 51 months 
(Figure 1). The median time from local therapy until a change 
in systemic therapy was 22 months (95% CI: 6–30 months) 
with a range from 1 to 54 months. During their clinical course 
after local therapy, 11 of 18 patients had cytotoxic chemo-
therapy, and six of 18 patients enrolled in a clinical trial. The 
median overall survival from local therapy was 41 months 
(95% CI: 26 months–not reached) (Figure 2), with a range 
from 1 to 65+ months. Outcomes for each patient receiving 
local therapy are described in Table 3.
 DISCUSSION
Patients with EGFR-mutant lung cancer have a unique 
clinical course, even after development of acquired resis-
tance to EGFR TKIs. No additional EGFR targeted therapies 
have been conclusively shown to be effective in this setting. 
Treatment options include participation in a clinical trial or 
standard cytotoxic chemotherapy with or without EGFR TKI 
continuation. Here we show that local therapy with surgery, 
radiation, or radiofrequency ablation in selected patients is 
associated with a median overall survival of 41 months, a 
median time to progression of 10 months, and a median time 
to next systemic therapy of 22 months. These remarkable out-
comes in patients with EGFR-mutant lung cancer are likely a 
result of multiple factors including the unique clinical course 
of this disease, patient selection, continued benefits of the TKI 
FIGURE 2.  Overall survival after local therapy
TABLE 3.  Outcomes for Individual Patients after Local Therapy
Patient Intervention Time to Progression (mo) Time to Treatment Change (mo) Time to Death (mo)
1 Lung lobectomy 1+a 1+ 1+
2 Lung SRSb 2+ 2+ 2+
3 Adrenalectomy 4+ 4+ 4+
4 Lymph node (mediastinal and supraclavicular) RTc 3 4 5+
5 Lung pneumonectomy 2 8 8
6 Lung RFA 2 3 18
7 Lung RFA 4 22+ 22+
8 Lung lobectomy 25+ 25+ 25+
9 Lung RTd 9 9 26
10 Lung lobectomy 15 16 26
11 Adrenalectomy 1 4 28
12 Lung pneumonectomy 21 21 29
13 Lung pneumonectomy 28 29 32+
14 Lung wedge 2 6 42
15 Lung lobectomy 12 30 43+
16 Lung lobectomy 45+ 45+ 45+
17 Lung lobectomy 51 54 64
18 Lung lobectomy 10 23 65+
a Indicates patients who have not died or progressed during study follow-up.
b Lung SRS was 4500cGy/5 fractions.
c Lymph node RT was 5000cGy/25 fractions.
d Lung RT was 6000cGy/3 fractions.
RT, radiation therapy; RFA, radiofrequency ablation; SRS, steroetactic radiosurgery.
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even after progression,18,20,35,36 and potential benefits of local 
therapy.
Patients with EGFR-mutant lung cancers have improved 
outcomes with the use of EGFR TKI therapy, but also have 
better results with chemotherapy and better surgical outcomes 
as well.7,37 Even with the development of acquired resistance, 
patients with EGFR-mutant lung cancers have superior sur-
vival with a median survival of 16 months after EGFR TKI 
progression38 compared with a median overall survival of 12 
months from diagnosis for patients with advanced non–small-
cell lung cancers not selected by EGFR genotype.39 Among 
patients with acquired resistance, outcomes vary; however, one 
analysis suggests that the emergence of the T790M point muta-
tion is associated with improved postprogression outcomes.38
Our data demonstrate that, in selected patients with 
acquired resistance, local therapy can lead to longer progression-
free intervals that seem to be superior to the responses 
historically seen with standard treatment options and can be 
done safely with minimal toxicities. The outcomes in patients 
who received local therapy may reflect in part the more indolent 
natural history of patients with limited sites of disease. In this 
cohort, the median time from diagnosis of advanced disease 
to local therapy was 26 months, indicating a more indolent 
disease course that predates any local therapy intervention. 
There were no other differences with a cohort of patients with 
EGFR-mutant lung cancers and acquired resistance who did not 
receive local therapy to suggest other factors useful for patient 
selection. Important differences between the two groups may 
not be apparent because of the small number of patients who 
received local therapy in our series.
Although the patients reported here had long median 
overall survivals and time to progressions, there was a wide 
range of outcomes. Outcomes seemed to best when the site of 
local therapy was the only known site of disease. Two patients 
progressed within 5 months with brain metastases and two 
other patients with shorter progression-free intervals had 
bone metastases at the time of local therapy. We suggest CNS 
imaging before any considered local therapy and avoiding 
local therapy in the setting of bone metastases unless the bone 
lesions are treated and stable over a prolonged period of time. 
In addition to analysis of clinical and molecular characteris-
tics, site of progression, and rate of tumor growth, similar to 
prostate-specific antigen velocity,40 may be helpful to identify 
patients most likely to have good outcomes after local therapy. 
Genomic analysis of growing metastatic sites compared with 
stable metastatic sites and/or the primary tumor may also pro-
vide useful information that may allow us to appropriately 
tailor the use of local therapy to patients who will derive the 
most benefit.41,42
There are several caveats in interpreting our data. Local 
therapies were only used in 10% of individuals with tumors 
with EGFR TKI acquired resistance, clearly a selected group 
of individuals. Almost all patients in this cohort contin-
ued erlotinib or gefitinib after local therapy. It is likely that 
this contributed to their favorable clinical outcomes as well. 
Prospective multicenter evaluation of local therapy is needed 
to define more clearly the patient population that may benefit 
from this treatment strategy.
There is currently no consensus on the optimal manage-
ment of patients whose tumors develop acquired resistance to 
EGFR TKIs. Our standard approach to treatment of EGFR-
mutant lung cancer with acquired resistance to EGFR TKI ther-
apy is based on burden of disease (especially the number and 
location of metastatic sites) and patient symptoms (see Fig. 3). 
If a patient has asymptomatic, indolent progression of disease 
on EGFR TKI, our practice is to continue erlotinib or gefitinib 
and to watch the patient for the development of clinical symp-
toms or an acceleration of disease progression. Despite progres-
sion on TKI therapy, there are data both in the laboratory18 and 
the clinic to suggest that the continuation of EGFR therapy is 
beneficial. All aspects of this treatment algorithm would benefit 
from prospective study. With the potential benefit of learning 
about a small-cell histologic transformation and the prognostic 
value of EGFR T790M, we biopsy patients at the time of devel-
opment of acquired resistance as part of routine care.
In this series, we show that local therapy for oligomet-
astatic disease can be a useful treatment option for patients 
with acquired resistance to EGFR TKI therapy. EGFR-mutant 
lung cancer typically has a more indolent natural history com-
pared with EGFR–wild-type disease, and a subset of EGFR 
mutant patients with oligometastatic disease may benefit from 
locally directed therapies. In these patients, local therapy leads 
to long progression-free survival, overall survival, and, with 
continued EGFR inhibition, prolonged time until a change in 
systemic therapy is required. These local therapies can usually 
be performed with minimal toxicity and result in months to 
years of disease control. Before proceeding with local therapy, 
patients should have the full extent of their disease evaluated. 
FIGURE 3.  An approach to man-
agement of patients with acquired 
resistance to EGFR TKI therapy
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Our experience suggests local therapy should be considered 
for patients with oligometastatic lung cancer with acquired 
resistance to EGFR TKI.
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